

Robert M Ward

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8224053/publications.pdf>

Version: 2024-02-01

31
papers

687
citations

623574

14
h-index

552653

26
g-index

31
all docs

31
docs citations

31
times ranked

843
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including) Tj ETQq1 1 0.784314 rgBT ₇₇ /Overlook	1.1	77
2	The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. Paediatric Anaesthesia, 2014, 24, 591-601.	0.6	67
3	Preaxial ray reduction defects as part of valproic acid embryofetopathy. Prenatal Diagnosis, 1993, 13, 909-918.	1.1	60
4	Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). European Journal of Clinical Pharmacology, 2010, 66, 555-561.	0.8	55
5	The Need for Pediatric Drug Development. Journal of Pediatrics, 2018, 192, 13-21.	0.9	53
6	Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. Pediatric Research, 2015, 78, 315-322.	1.1	42
7	Development of a neonatal adverse event severity scale through a Delphi consensus approach. Archives of Disease in Childhood, 2019, 104, 1167-1173.	1.0	40
8	Drug Therapy of the Fetus. Journal of Clinical Pharmacology, 1993, 33, 780-789.	1.0	34
9	A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2016, 101, F236-F243.	1.4	32
10	Criteria supporting the study of drugs in the newborn. Clinical Therapeutics, 2006, 28, 1385-1398.	1.1	25
11	Pediatric Age Groups and Approach to Studies. Therapeutic Innovation and Regulatory Science, 2019, 53, 584-589.	0.8	25
12	Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. Pediatric Research, 2013, 74, 721-729.	1.1	21
13	Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE). Pediatric Research, 2020, 88, 629-636.	1.1	21
14	Administration of Inhaled Pulmonary Vasodilators to the Mechanically Ventilated Neonatal Patient. Paediatric Drugs, 2017, 19, 183-192.	1.3	15
15	Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates. BMC Pharmacology & Toxicology, 2016, 17, 22.	1.0	14
16	Principles of Pharmacokinetics in the Pregnant Woman and Fetus. Clinics in Perinatology, 2019, 46, 383-398.	0.8	14
17	Ethics of Drug Studies in the Newborn. Paediatric Drugs, 2015, 17, 37-42.	1.3	13
18	Albuterol delivery in a neonatal ventilated lung model: Nebulization versus chlorofluorocarbon- and hydrofluoroalkane-pressurized metered dose inhalers. Pediatric Pulmonology, 2001, 31, 247-254.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Drug Disposition in the Late Preterm (‘Near-Term’) Newborn. <i>Seminars in Perinatology</i> , 2006, 30, 48-51.	1.1	12
20	Commentary. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 606-607.	1.1	9
21	Applying Regulatory Science to Develop Safe and Effective Medicines for Neonates: Report of the US Food and Drug Administration First Annual Neonatal Scientific Workshop, October 28-29, 2014. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 623-631.	0.8	9
22	Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1237-1244.	1.6	7
23	Neonatal Medications. <i>Pediatric Clinics of North America</i> , 2015, 62, 525-544.	0.9	4
24	Pharmacometrics in Pediatrics. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 579-583.	0.8	4
25	Supportive care medications coinciding with chemotherapy among children with hematologic malignancy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1920-1931.	0.6	4
26	History of Children and the Development of Regulations at the FDA. , 0, , 6-15.		4
27	Regulation of CYP3A genes by glucocorticoids in human lung cells. <i>F1000Research</i> , 2013, 2, 173.	0.8	4
28	Inositol Analysis by HPLC and Its Stability in Scavenged Sample Conditions. , 2015, 5, 077-80.		3
29	Development of a severity scale to assess chronic lung disease after extremely preterm birth. <i>Pediatric Pulmonology</i> , 2021, 56, 1583-1592.	1.0	3
30	QTc Intervals Are Prolonged in Late Preterm and Term Neonates during Therapeutic Hypothermia but Normalize Afterwards. <i>Children</i> , 2021, 8, 1153.	0.6	3
31	Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 747-765.	1.5	1